Skip to main content
U.S. flag

An official website of the United States government

LBD: Develop neuroimaging markers of disease progression (Milestone 9.O)

In Progress

Timeline Start - End

2016 - 2027

Research Implementation Area


AD-Related Dementias Focus

LBD Clinical Characterization and Intervention: Develop and refine neuroimaging biomarkers that track progression, assist in differential diagnosis, provide therapeutic target engagement, and relate to pathology. 

Success Criteria

  • At least two new studies that evaluate, improve, develop, validate, and standardize clinical trial ready LBD neuroimaging biomarkers for the diagnosis, diagnosis, and progression of LBD that are sensitive and specific versus similar disorders. 
  • At least one clinically validated LBD neuroimaging biomarker that is clinical trial ready. 

Summary of Key Accomplishments

Several NIH-funded studies are working to develop imaging markers for LBD. For example, a recently published study found a particular PET imaging measure could help predict whether an individual exhibiting early signs of cognitive decline would go on to develop AD or dementia with Lewy bodies (DLB). In another study, researchers used MRI to assess iron levels in one part of the brain known as the substantia nigra, and they reported that iron levels tended to increase as the severity of DLB increased.

Further evaluation of elevated iron levels as a useful MRI biomarker for disease progression/severity in DLB in a larger number of individuals with DLB will be conducted via the NIH-funded North American Prodromal Synucleinopathy Consortium for REM Sleep Behavior Disorder.

The key accomplishments summary is current as of July 2022.  

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health